foretinib
Small moleculeexperimental
Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of October 2015 it appears development has been discontinued. — Wikipedia
Clinical trial activity
11 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00742131)
Timeline
Indications
Mechanism of action
Platelet-derived growth factor receptor inhibitor
Vascular endothelial growth factor receptor inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
FLT3 inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1- Mol. weight
- 632.66 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaForetinib ↗
- ChEMBLCHEMBL1230609 ↗
Also known as
- exel 2880
- exel-2880
- exel-2880
- exel-2880
- foretinib
- foretinib
- foretinib
- foretinib
- foretinib
- gsk089
- gsk089
- gsk1363089
- gsk1363089
- gsk1363089
- gsk 1363089
- gsk-1363089
- gsk-1363089
- gsk-1363089
- gsk1363089g
- gsk1363089g
- xl 880
- xl-880
- xl-880
- xl-880
- xl880 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02034097 | Phase 2 | Apr 1, 2014 | GlaxoSmithKline |
| NCT01138384 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2010 | British Columbia Cancer Agency, Canadian Cancer Trials Group |
| NCT01147484 | Phase 2 | May 1, 2010 | Canadian Cancer Trials Group, University of Adelaide, University of Calgary |
| NCT01068587 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2009 | British Columbia Cancer Agency, Canadian Cancer Trials Group, University of Toronto |
| NCT00920192 | Phase 1 | Aug 12, 2009 | GlaxoSmithKline |
| NCT00742261 | Phase 1 | Aug 1, 2008 | GlaxoSmithKline |
| NCT00725764 | Phase 2 | Aug 1, 2007 | GlaxoSmithKline |
| NCT00725712 | Phase 2 | Mar 1, 2007 | GlaxoSmithKline |
| NCT00743067 | Phase 1 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00726323 | Phase 2 | Jun 1, 2006 | GlaxoSmithKline |
| NCT00742131 | Phase 1 | Mar 1, 2005 | GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 8 | 8 | 2 | 2005 |
| Canadian Cancer Trials Group | Academic/Hospital | 3 | 3 | 1 | 2009 |
| British Columbia Cancer Agency | Academic/Hospital | 2 | 0 | 1 | 2009 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Calgary | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1